Repository logo
 

Androgen receptor function and targeted therapeutics across breast cancer subtypes.

Accepted version
Peer-reviewed

No Thumbnail Available

Type

Article

Change log

Authors

Kolyvas, Emily A 
Caldas, Carlos 
Kelly, Kathleen 

Abstract

Despite significant progress in breast cancer (BC) therapy, it is globally the most commonly diagnosed cancer and leads to the death of over 650,000 women annually. Androgen receptor (AR) is emerging as a potential new therapeutic target in BC. While the role of AR is well established in prostate cancer (PCa), its function in BC remains incompletely understood. Emerging data show that AR's role in BC is dependent on several factors including, but not limited to, disease subtype, tumour microenvironment, and levels of circulating oestrogens and androgens. While targeting AR in PCa is becoming increasingly effective, these advances have yet to make any significant impact on the care of BC patients. However, this approach is increasingly being evaluated in BC and it is clear that improvements in our understanding of AR's role in BC will increase the likelihood of success for AR-targeted therapies. This review summarizes our current understanding of the function of AR across BC subtypes. We highlight limitations in our current knowledge and demonstrate the importance of categorizing BC subtypes effectively, in relation to determining AR activity. Further, we describe the current state of the art regarding AR-targeted approaches for BC as monotherapy or in combination with radiotherapy.

Description

Keywords

Androgen deprivation therapy, Androgen receptor, Breast cancer, DNA damage repair, Radiotherapy, Humans, Male, Receptors, Androgen, Androgens, Breast Neoplasms, Prostatic Neoplasms, Signal Transduction, Tumor Microenvironment

Journal Title

Breast Cancer Res

Conference Name

Journal ISSN

1465-5411
1465-542X

Volume Title

Publisher

BioMed Central
Sponsorship
Sorry not sure about rights retention - but can check as needed